177 related articles for article (PubMed ID: 34830977)
1. Oligoprogression in Non-Small Cell Lung Cancer.
Harada D; Takigawa N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830977
[TBL] [Abstract][Full Text] [Related]
2. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
3. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gan GN; Weickhardt AJ; Scheier B; Doebele RC; Gaspar LE; Kavanagh BD; Camidge DR
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):892-8. PubMed ID: 24462383
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
6. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
[TBL] [Abstract][Full Text] [Related]
7.
Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
9. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract][Full Text] [Related]
10. Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
Peeters STH; Van Limbergen EJ; Hendriks LEL; De Ruysscher D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925139
[TBL] [Abstract][Full Text] [Related]
11. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
12. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
13. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
14. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
15. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
Tjong MC; Louie AV; Iyengar P; Solomon BJ; Palma DA; Siva S
Transl Lung Cancer Res; 2021 Jul; 10(7):3446-3456. PubMed ID: 34430379
[TBL] [Abstract][Full Text] [Related]
16. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.
Simone CB; Burri SH; Heinzerling JH
Transl Lung Cancer Res; 2015 Oct; 4(5):545-52. PubMed ID: 26629423
[TBL] [Abstract][Full Text] [Related]
17. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
Kroeze SGC; Schaule J; Fritz C; Kaul D; Blanck O; Kahl KH; Roeder F; Siva S; Verhoeff JJC; Adebahr S; Schymalla MM; Glatzer M; Szuecs M; Geier M; Skazikis G; Sackerer I; Lohaus F; Eckert F; Guckenberger M
Radiat Oncol; 2021 Jan; 16(1):4. PubMed ID: 33407611
[TBL] [Abstract][Full Text] [Related]
18. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
19. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer.
Porcelli T; Sessa F; Luongo C; Salvatore D
J Endocrinol Invest; 2019 Aug; 42(8):871-879. PubMed ID: 30628046
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
